Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways

Current Approach Of Phase III Studies ‘Is No Longer Justified In Many Cases’

 
• By Dave Wallace
  
Pierre Bourdage, Sandoz head of biopharmaceuticals
Sandoz’s Pierre Bourdage sets out the case for tailored biosimilar development • Source: Sandoz

More from Biosimilars

More from Products